Skip to content
Screener

Alkermes ALKS Operating Income

Operating Income at other companies

Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
$336.6M+702%
AbbVie logo
AbbVieABBV
$6.43B+31.4%
Axsome Therapeutics logo
Axsome TherapeuticsAXSM
-$63.36M-11.2%
Indivior Pharmaceuticals, Inc. logo
Indivior Pharmaceuticals, Inc.INDV
$137M+108%
Harmony Biosciences Holdings, Inc. logo
Harmony Biosciences Holdings, Inc.HRMY
$37.29M-33.7%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
-$102.29M-173%

Other financials

Income statement

See full
Revenue$496.0M+27.0%
Gross profit$397.9M+16.6%
Net income$501.0K-99.4%
EPS (diluted)$0.00-100%

Balance sheet

See full
Cash & equivalents$511.5M-1.9%
Total debt$1.6B+2,064%
Total equity$1.8B+11.3%
Total assets$4.4B+95.0%

Cash flow

See full
Operating cash flow-$165.7M-268%
CapEx$8.1M-37.4%
Free cash flow-$169.8M-291%

Valuation

See full
Market cap$8.32B+89.9%
Enterprise value$9.38B+139%
P/E125.9×+113×
P/S+2.1×

Profitability

See full
Gross margin84.6%-0.6pp
Operating margin7%-17.8pp
Net margin4%-19.2pp
FCF margin14.2%-17.6pp

Returns & leverage

See full
Return on equity3.9%-20.1pp
Debt / equity0.9×+0.8×
Current ratio2.3×-0.9×

Where this comes from

Reported directly by Alkermes in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The source filing: Alkermes’s 10-Q, filed July 28, 2026.

Filed
Jul 28, 2026, 9:22 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-319022
Line itemThree Months Ended / June 30, 2026Three Months Ended / June 30, 2025Six Months Ended / June 30, 2026Six Months Ended / June 30, 2025
Change in fair value of contingent consideration26,41426,414
Amortization of acquired intangible assets22,58534,260
Total expenses477,656297,679918,847590,397
OPERATING (LOSS) INCOME18,35392,978(29,927)106,770
OTHER (EXPENSE) INCOME, NET:
Interest income5,34411,09013,88321,231
Interest expense(25,925)(46,817)
Other (expense) income, net352771(941)2,327

Item 1. Condensed Consolidated Financial Statements:

FAQ

What is Alkermes's operating income?
Alkermes (ALKS) reported operating income of $18.35M in Q2 2026.
How has Alkermes's operating income changed year-over-year?
Alkermes's operating income decreased by 80.3% year-over-year, from $92.98M to $18.35M.
What is the long-term trend for Alkermes's operating income?
Over 4 years (2021 to 2025), Alkermes's operating income has grown at a 68.3% compound annual growth rate (CAGR), from -$31.67M to $253.96M.
What does operating income mean?
Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.

Ask your AI about Alkermes's operating income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude